| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
37,090,000 |
| Market
Cap: |
28.60(M) |
| Last
Volume: |
1,764,528 |
Avg
Vol: |
1,759,649 |
| 52
Week Range: |
$0.439 - $2.125 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Viracta Therapeutics is a precision oncology company focused on the development of medicines targeting virus-associated malignancies. Co.'s main program is focused on cancers associated with the Epstein-Barr virus (EBV). Co.'s main product candidate is an all-oral combination therapy of its investigational drug, nanatinostat and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is being investigated in clinical trials, including NAVAL-1, a trial for the treatment of multiple subtypes of relapsed/refractory EBV-positive (EBV+) lymphoma, as well as a trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
100,000 |
100,000 |
100,000 |
| Total Buy Value |
$0 |
$49,361 |
$49,361 |
$49,361 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
2 |
2 |
2 |
| Total Shares Sold |
3,405 |
7,125 |
14,272 |
63,811 |
| Total Sell Value |
$2,493 |
$4,353 |
$14,605 |
$152,715 |
| Total People Sold |
1 |
1 |
1 |
3 |
| Total Sell Transactions |
1 |
2 |
4 |
14 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Royston Ivor |
CEO & President |
• • – |
2022-02-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,219 |
603,508 |
|
- |
|
| Chevallard Daniel R. |
CFO and COO |
• – – |
2022-02-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,889 |
79,847 |
|
- |
|
| Royston Ivor |
CEO & President |
• • – |
2021-12-29 |
4 |
OE |
$0.90 |
$6,300 |
D/D |
7,000 |
578,289 |
|
- |
|
| Royston Ivor |
CEO & President |
• • – |
2021-11-15 |
4 |
B |
$5.56 |
$44,480 |
D/D |
8,000 |
548,599 |
2.81 |
-15% |
|
| Chevallard Daniel R. |
CFO and COO |
• – – |
2021-09-28 |
4 |
OE |
$0.90 |
$9,000 |
D/D |
10,000 |
66,760 |
|
- |
|
| Chevallard Daniel R. |
CFO and COO |
• – – |
2021-05-28 |
4 |
OE |
$0.90 |
$10,800 |
D/D |
12,000 |
56,760 |
|
- |
|
| Rojkjaer Lisa |
Chief Medical Officer |
• – – |
2021-05-11 |
4 |
OE |
$1.26 |
$48,567 |
D/D |
34,750 |
34,750 |
|
- |
|
| Schindel Yair Chaim |
10% Owner |
– – • |
2021-02-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,032,865 |
|
120% |
|
| Schindel Yair Chaim |
10% Owner |
– – • |
2021-02-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,359,372 |
|
120% |
|
| Roshwalb Gur |
Director |
– • • |
2021-02-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
7,392,237 |
|
120% |
|
| Royston Ivor |
CEO & PresidentOfficer |
• • – |
2021-02-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
18,599 |
|
120% |
|
| Royston Ivor |
CEO & PresidentOfficer |
• • – |
2021-02-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
540,599 |
|
120% |
|
| Chevallard Daniel R. |
Chief Executive OfficerOfficer |
• – – |
2021-02-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
44,760 |
|
120% |
|
| Hyare Parvinder S |
See RemarksOfficer |
• – – |
2021-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
960 |
|
236% |
|
| Gullotta Tina |
VP, Finance |
• – – |
2020-05-29 |
4 |
B |
$0.33 |
$1,989 |
D/D |
6,000 |
20,500 |
2.66 |
- |
|
| Gullotta Tina |
VP, FinanceOfficer |
• – – |
2020-04-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,500 |
|
- |
|
| Quinn William P. |
See Remarks |
• – – |
2019-11-29 |
4 |
B |
$0.37 |
$2,193 |
D/D |
6,000 |
127,697 |
2.66 |
- |
|
| Elms Steve |
10% Owner |
– – • |
2019-07-15 |
4 |
B |
$0.60 |
$1,500,000 |
I/I |
2,500,000 |
10,100,000 |
1.5 |
- |
|
| Quinn William P. |
See Remarks |
• – – |
2019-05-31 |
4 |
B |
$0.65 |
$3,877 |
D/D |
6,000 |
121,697 |
2.66 |
- |
|
| Fox Judith A. |
Chief Scientific OfficerOffice |
• – – |
2019-03-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
40,268 |
|
- |
|
| Quinn William P. |
See Remarks |
• – – |
2019-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
63,697 |
115,697 |
|
- |
|
| Quinn William P. |
CFO,Sr.V.P. Finance, Corp.Dev. |
• – – |
2018-12-10 |
4 |
B |
$0.47 |
$18,800 |
D/D |
40,000 |
52,000 |
2.74 |
- |
|
| Ubs Oncology Impact Fund L.p. |
10% Owner |
– – • |
2017-11-06 |
4 |
B |
$2.77 |
$44,874 |
I/I |
16,200 |
3,331,500 |
1.5 |
- |
|
| Ubs Oncology Impact Fund L.p. |
10% Owner |
– – • |
2017-11-03 |
4 |
B |
$2.89 |
$115,600 |
I/I |
40,000 |
3,315,300 |
1.5 |
- |
|
| Ubs Oncology Impact Fund L.p. |
10% Owner |
– – • |
2017-11-02 |
4 |
B |
$2.59 |
$65,527 |
I/I |
25,300 |
3,275,300 |
1.5 |
- |
|
163 Records found
|
|
Page 3 of 7 |
|
|
0.01 (1.45%) 
